Meitheal Pharmaceuticals said on Thursday that it has received USD95m for a majority stake investment in the company from Hong Kong King-Friend Industrial Company (HKF), a wholly-owned subsidiary of Nanjing King-Friend Biochemical Pharmaceutical Company (NKF).
Based in China, NKF is principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF).
Upon closing of the transaction, Meitheal is now majority-owned by NKF and will serve as its exclusive commercialisation arm in the US.
Based in Chicago, Illinois, Meitheal is a supplier of affordable generic injectables. Its diversified products include antibiotics, anticoagulants, muscle relaxants and drugs used in chemotherapy.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US